Avenzo Therapeutics, Merck KGaA and AbbVie each inked new deals to top up their cancer pipelines, with the former two companies handing over a combined $85 million in upfront cash. Avenzo disclosed Thursday that it has locked arms with Allorion Therapeutics, snapping up ex-Greater China rights to the early-stage CDK2 blocker AVZO-021. The enzyme has […]

Author